All In Biotech

Drug Trial Radar · NCT02588677

Masitinib in Combination With Riluzole for the Treatment of Patients Suffering From Amyotrophic Lateral Sclerosis (ALS)

Multicenter, Randomised, Double-blind, Placebo-controlled, Parallel Group, Phase 2/3 Study to Compare the Efficacy and Safety of Masitinib

Last checked: Nov 19, 2026Latest source record: Sep 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 394 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

394

Actual

Start

Apr 2013

Primary completion

Dec 5, 2016

Study completion Mar 2018

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Oct 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to compare the efficacy and safety of masitinib in combination with riluzole in the treatment of patients suffering from Amyotrophic Lateral Sclerosis (ALS).

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

  • Masitinib (4.5)Drug

    4.5 mg/kg/day

  • RiluzoleDrug

  • PlaceboDrug

  • Masitinib (3.0)Drug

    3 mg/kg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Amyotrophic Lateral Sclerosis functional rating scale (ALSFRS)-RevisedTime frame: From baseline to week 48

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital Carlos III

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.